Creating a World for Patients Where Healthcare Has No Limits

 

Significant advances in diagnostic imaging have the potential to personalize care. We are deeply committed to ensuring that the Metastatic Breast Cancer (MBC) community gains greater familiarity with the expanding and critical role of molecular imaging in patient care, and that people living with MBC as well as their loved ones have access to relevant resources and tools which may guide more informed discussion with their healthcare team.


GE HealthCare Oncology Imaging Agents


CERIANNA™ (fluoroestradiol F18) injection is the first FDA approved diagnostic imaging agent to detect estrogen receptor-positive (ER+) lesions in recurrent or MBC as an adjunct to biopsy. Because your overall ER+ status can change over the course of disease or even in response to treatment1 , using Cerianna may help your healthcare team in making a more informed clinical decision2.



Learn more about Cerianna through patient stories, educational resources, and programs hosted/developed by GE HealthCare and/or our advocacy partners.



11. Kurland BF et al. J Nucl Med 2011;52:1541–9; 2. Currin E et al. J Natl Compr Canc Netw 2016;14:144–7; 3. Lower EE et al. Breast Cancer (Dove Med Press) 2017;9:515–20

1Amir E et al. J Clin Oncol 2012;30:587; Criscitiello C et al. Breast Cancer Res 2014;16:205; Boers J et al. Eur J Cancer 2020;126:11–20



Susan G Komen® and GE HealthCare Partner to Improve Lives and Raise Awareness of Advancements in Diagnostic and Treatment Options for Metastatic Breast Cancer – Learn More

 Meet Our Patient Ambassadors

Alexandra is a personal trainer in Beverly Hills, California, and a member of the Hollywood elite.  Read Alexandra’s story here.

Kimberly is an event planner at Disney and longtime volunteer with Susan G. Komen.  Read Kimberly’s story here, or watch here .  

Jamil is the founder and CEO of the Chrysalis Initiative  and fierce health equity advocate particularly for Black women and other disadvantaged groups, and has been featured in People Magazine, the Philadelphia Inquirer, the Philadelphia Tribune, as well as on CBS News and Good Morning America – among others.  Learn more about Jamil here.  

 

Their journey through diagnosis and treatment was unequivocally unique, and so was their diagnostic imaging test.  




CERIANNA INDICATION AND IMPORTANT SAFETY INFORMATION FOR NON-HEALTHCARE PROFESSIONALS

 

CERIANNATM (fluoroestradiol F18) injection is a diagnostic imaging agent (sometimes called a

radiopharmaceutical or tracer). CERIANNA is used as part of a Positron Emission Tomography (PET) scan to detect a specific protein called the estrogen receptor on breast cancer tumors that have recurred or spread from their original site (metastasized). CERIANNA is used as an adjunct to biopsy.

 

Adverse Reactions: The most common side effects seen with CERIANNA were pain at the site of injection and temporary altered taste sensation.

Radiation Risks: CERIANNA is radioactive and exposure to radiation has a dose dependent increased risk of cancer. Please discuss with your doctor about ways to help minimize this risk.

Risk of Misdiagnosis: CERIANNA imaging results can have false negatives and false positives. Please discuss any concerns with your doctor.

Use in Specific Populations: Tell your doctor if you are or may be pregnant; if you plan on becoming pregnant; or you are currently breastfeeding.

 

Additionally, CERIANNA has not been studied in patients under the age of 18.

 

CERIANNA is expected to behave similarly in adult patients, regardless of age.

 

To report SUSPECTED ADVERSE REACTIONS, contact Zionexa US Corp, a GE Healthcare Company at +1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

 
 

 

 

GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe

500 W. Monroe Street | Chicago, IL 60661

 

© 2023 GE HealthCare
GE is a trademark of General Electric Company used under trademark license.


JB07654US